Phase II/III

Type: Keyphrase
Name: Phase II/III
First reported 14 hours ago - Updated 2 hours ago - 3 reports

ALK's strategic partner Torii in final stage of clinical development for Japanese cedar allergy

Japanese drugmaker Torii Pharmaceutical has begun a Phase II/III development program with Denmark-based allergy specialist ALK Abello (ALKB: DC) for a new allergy immunotherapy tablet to treat Japanese cedar tree pollen allergy.Torii, a strategic partner ... [Published Pharma Letter - 2 hours ago]
Entities: Cedar, Pollen, Immunotherapy
First reported 3 hours ago - Updated 3 hours ago - 1 reports

bluebird bio poised to advance gene therapy pipeline02-09-2014

US clinical-stage biotech firm bluebird bio (Nasdaq: BLUE) is advancing a pipeline focused on gene therapy, a rapidly expanding area that has attracted significant industry interest, note analysts at Edison Equity Research in a note on the company.bluebird ... [Published Pharma Letter - 3 hours ago]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Isis Earns $1M in Another Milestone Payment from GSK

Isis Pharmaceuticals received a $1 million milestone payment from GlaxoSmithKline ( GSK ) as part of an open-label extension study of ISIS-TTRRx. The product is being offered to patients with familial amyloid polyneuropathy (FAP) who have completed dosing ... [Published Genetic Engineering News - Aug 29 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Novartis circles back with new terms for a stem cell biotech buyout - report

Novartis' on-again, off-again deal to buy out Israeli stem cell therapy developer Gamida Cell is reportedly back on again--though the pharma giant has apparently renegotiated the old $600 million pact to include a smaller upfront buy-in and one of its ... [Published FierceBiotech - Aug 18 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

How Much Should Clinical Trials Pay Participants?

Answering this question takes some deliberation, according to experts, since compensation may interfere with good research. On the other hand, participants, without whom medical science would grind to a halt without, deserve some kind of compensation ... [Published ABC 4 - Aug 13 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 2 reports

Can Fite Biopharma Ltd shows high efficacy for Can-Fite's CF101 in rheumatoid arthritis and psoriasis patients

12:00pm BST Can Fite Biopharma Ltd:Says new data from retrospective analysis of its autoimmune disease advanced trials that shows high efficacy of orally bioavailable drug CF101.Retrospective study, conducted by third party statistician group, analyzed ... [Published Reuters UK - Aug 06 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

GENESYS : Cold Genesys Secures $13.57M in a Series A Round of Financing

Cold Genesys, Inc. ("CGI") reported that it has secured Series A financing of $13.57 million from Ally Bridge Group .According to a release, CGI will deploy the capital to advance its ongoing Phase II/III BOND trial which is evaluating CG0070 in patients ... [Published 4 Traders - Aug 04 2014]
First reported Jul 31 2014 - Updated Aug 01 2014 - 3 reports

Cold Genesys gets $13.6M Series A for oncolytic virus that targets bladder cancer

Cold Genesys , a sort of latter-day spinoff of the once-promising cancer vaccine maker Cell Genesys, has an engineered oncolytic virus that shows promise in treating a dangerous form of bladder cancer. The Newport Beach, California company just received ... [Published MedCity News - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Cold Genesys Raises $13.57 Million in a Series A Round of Financing to Accelerate Its Ongoing Phase II/III Clinical Trial for Bladder Cancer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Cold Genesys, Inc., a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer, announced today that it has secured financing of $13.57 million from Ally Bridge Group. ... [Published Business Wire Health News - Jul 30 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 2 reports

AgeneBio Appoints Industry Leaders Patrick LePore as Chairman of the Board and Jerry McLaughlin as President and Chief Executive Officer

BALTIMORE, MD -- (Marketwired) -- 07/25/14 -- AgeneBio, Inc., a clinical-stage pharmaceutical company developing medicines to restore and preserve patients' cognitive function for a range of debilitating neurodegenerative diseases, today announced the ... [Published TVNewsCheck - Jul 25 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 1 reports

Can-Fite Completes Patient Enrollment in its Phase II/III Psoriasis Trial; Final Results are expected in Q1 2015

PETACH TIKVA, Israel, June 17, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has ... [Published PR Newswire: Health - Jun 17 2014]
First reported Jun 10 2014 - Updated Jun 10 2014 - 2 reports

CanFite to Participate in Newport Coast Securities Conference in New York & ROTH Conference in London

/PRNewswire/ --  Can-Fite BioPharma Ltd . (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Chief Financial Officer, Motti ... [Published BioPortfolio - Jun 10 2014]

Quotes

Marc Oczachowski, EDAP's Chief Executive Officer, stated, "During the second quarter, we continued to see solid revenue growth worldwide, mainly driven by increasing demand for our HIFU devices in Europe and the rest of the world. This clearly demonstrates a growing adoption and recognition of HIFU in treating prostate cancer and EDAP's ability to answer both urologist and patient needs with our unique full range of HIFU products, including Ablatherm-HIFU and Focal One."
Marc Oczachowski, Chief Executive Officer of EDAP TMS, commented, "As discussions on best prostate cancer treatment strategies continue among urologists, such international symposiums represent a great opportunity to review the latest in technologies and clinical strategies. Focal One was highlighted multiple times within the scientific program clearly establishing its lead in the field. With our long term worldwide experience in HIFU and the current growing interest in focal therapy, our teams of international experts are already contributing to strategic discussions and decisions on prostate cancer treatment strategies."
"The addition of Ally Bridge Group as a strategic investor at this critical juncture of our CG0070 program for NMIBC not only enables us to complete the Phase III portion of the BOND trial, but also allows us to immediately develop other treatment options in advanced bladder cancer, as well as in other solid tumors" said Dr. Alex Yeung , President and CEO of Cold Genesys
"These new findings are further evidence of CF101's high efficacy, while the drug continues to show excellent safety in patients. We believe the data will be very important to the design of our forthcoming Phase III trials because these findings help us to achieve the maximum potential of the drug in the treatment of inflammatory conditions" stated Can-Fite CEO Pnina Fishman

More Content

All (60) | News (48) | Reports (0) | Blogs (9) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
ALK's strategic partner Torii in final stage of... [Published Pharma Letter - 2 hours ago]
bluebird bio poised to advance gene therapy pip... [Published Pharma Letter - 3 hours ago]
ALK's partner Torii initiates final stage of cl... [Published GlobeNewswire - 14 hours ago]
ALK's partner Torii initiates final stage of cl... [Published EuroInvestor - 14 hours ago]
Isis Earns $1M in Another Milestone Payment fro... [Published Genetic Engineering News - Aug 29 2014]
EDAP Reports Strong Growth in Its Second Quarte... [Published WGNT - Aug 28 2014]
Variability in Response to Rituximab in Autoimm... [Published General Medicine eJournal - Aug 27 2014]
EDAP Highlights HIFU Expertise at 7th Internati... [Published Franklin Credit Management Corporation - Aug 26 2014]
Novartis slashes ante, inks another Gamida Cell... [Published FierceBiotech - Aug 19 2014]
Novartis circles back with new terms for a stem... [Published FierceBiotech - Aug 18 2014]
CSL's (CMXHF) CEO Paul Perreault on Q4 2014 Res... [Published Seeking Alpha - Aug 14 2014]
Soligenix (SNGX): Conservative Cash Burn Couple... [Published Yahoo! Finance - Aug 13 2014]
GENESYS : Cold Genesys Gets $13.57M in a Series... [Published 4 Traders - Aug 13 2014]
How Much Should Clinical Trials Pay Participants? [Published ABC 4 - Aug 13 2014]
EDAP Schedules Webcast and Conference Call for ... [Published InvestorPoint.com - Aug 11 2014]
Synta Pharmaceuticals (SNTA) Q2 2014 Results - ... [Published Seeking Alpha - Aug 06 2014]
Can Fite Biopharma Ltd shows high efficacy for ... [Published Reuters UK - Aug 06 2014]
New Data Shows High Efficacy for Can-Fite's CF1... [Published TickerTech.com - Aug 06 2014]
CROs Slowly Shifting to Adaptive Clinical Trial... [Published Outsourcing Pharma - Aug 05 2014]
EDAP Comments on FDA Panel Vote [Published Ask.com - Aug 05 2014]
Positive PEA for Goldsources’s Eagle Mountain [Published Mining & Quarry World - Aug 04 2014]
Cold Genesys Reports Series A Round of Financing [Published Individual.com - Aug 04 2014]
GENESYS : Cold Genesys Secures $13.57M in a Ser... [Published 4 Traders - Aug 04 2014]
GENESYS : Cold Genesys Secures $13.57M in a Ser... [Published 4 Traders - Aug 04 2014]
Pacira Pharmaceuticals' (PCRX) CEO Dave Stack o... [Published Seeking Alpha - Aug 01 2014]
Cold Genesys gets $13.6M Series A for oncolytic... [Published MedCity News - Jul 31 2014]
Cold Genesys rakes in $13.6M for its cancer-fig... [Published FierceBiotech - Jul 31 2014]
Cold Genesys snags $13.57 mln Series A [Published PE Hub Blog - Jul 31 2014]
EDAP Updates on FDA Advisory Committee Meeting ... [Published Benzinga.com - Jul 30 2014]
Cold Genesys Raises $13.57 Million in a Series ... [Published Business Wire Health News - Jul 30 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Cold Genesys snags $13.57 mln Series A [Published PE Hub Blog - Jul 31 2014]
Cold Genesys has raised $13.57 million in Series A financing from Ally Bridge Group . Based in Newport Beach, Calif., CGI is a clinical-stage biopharmaceutical firm developing oncolytic immunotherapies for cancer. PRESS RELEASE NEWPORT BEACH, Calif., ...
Cold Genesys Raises $13.57 Million in a Series ... [Published Business Wire Health News - Jul 30 2014]
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Cold Genesys, Inc., a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer, announced today that it has secured financing of $13.57 million from Ally Bridge Group. ...
AgeneBio Appoints Industry Leaders Patrick LePo... [Published Marketwire - Breaking News Releases - Jul 25 2014]
Appointments Complete Leadership Team to Advance Development Programs Including a Product Candidate in Phase II/III to Slow the Progression of Alzheimer's Disease ...
Can-Fite Completes Patient Enrollment in its Ph... [Published PR Newswire: Health - Jun 17 2014]
PETACH TIKVA, Israel, June 17, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has ...
Kamada Announces Preliminary Results from Phase... [Published Business Wire Health News - May 16 2014]
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada ...
1 2

Press Releases

sort by: Date | Relevance
ALK’s partner for Japan announces trial results... [Published GlobeNewswire: Acquisitions News - Jun 16 2014]
ALK’s partner for Japan reports positive trial ... [Published GlobeNewswire: Advertising News - Mar 10 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.